PMID- 23297825
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20211203
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 13
IP  - 3
DP  - 2013 Mar
TI  - Targeting the mTOR pathway in tumor malignancy.
PG  - 267-77
AB  - The mammalian target of rapamycin (mTOR) plays a critical role in the regulation 
      of cell growth, proliferation,and metabolism by integrating growth factor 
      stimulation and energy/nutrient input through a complex signaling network.The 
      mTOR kinase is a part of two structurally and functionally distinct multiple 
      protein complexes, mTORC1 and mTORC2. The mammalian target of rapamycin complex 1 
      (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by 
      regulating several cellular processes, such as translation, transcription, and 
      nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is 
      in sensitive to rapamycin and is involved in spatial control of cell growth via 
      cytoskeleton regulation. Here we discuss the mechanism of mTOR regulation in 
      tumor malignancy through a variety of signaling pathways and the potential of 
      mTOR inhibitors for the treatment of cancer.
FAU - Cheng, Hengmiao
AU  - Cheng H
AD  - Pfizer Worldwide Research and Development, 10724 Science Center Drive, San Diego, 
      CA 92121, USA.
FAU - Walls, Marlena
AU  - Walls M
FAU - Baxi, Sangita M
AU  - Baxi SM
FAU - Yin, Min-Jean
AU  - Yin MJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Isoenzymes)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Cell Transformation, Neoplastic/drug effects/metabolism
MH  - Humans
MH  - Isoenzymes/antagonists & inhibitors/metabolism
MH  - *Molecular Targeted Therapy
MH  - Neoplasm Proteins/*antagonists & inhibitors/metabolism
MH  - Neoplasms/*drug therapy/metabolism/prevention & control
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
EDAT- 2013/01/10 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/01/10 06:00
PHST- 2011/10/10 00:00 [received]
PHST- 2012/07/24 00:00 [revised]
PHST- 2013/01/28 00:00 [accepted]
PHST- 2013/01/10 06:00 [entrez]
PHST- 2013/01/10 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - CCDT-EPUB-20130102-3 [pii]
AID - 10.2174/1568009611313030005 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2013 Mar;13(3):267-77. doi: 
      10.2174/1568009611313030005.